New Drug Approvals

Home » Articles posted by DR ANTHONY MELVIN CRASTO Ph.D (Page 404)

Author Archives: DR ANTHONY MELVIN CRASTO Ph.D

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,819,127 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Celgene: Apremilast For Psoriatic Arthritis successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.


Celgene data from its ongoing Phase III trial of apremilast this month showing the drug successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.

The data is good news for the 1 million diagnosed patients in the U.S. and Europe and for shareholders eager to see apremilast win market share in the multibillion dollar immunology market.

read all at

 

http://seekingalpha.com/article/1433601-celgene-apremilast-for-psoriatic-arthritis-offers-upside?source=google_news

Scientists reveal drinking champagne could improve memory


(Medical Xpress)—New research shows that drinking one to three glasses of champagne a week may counteract the memory loss associated with ageing, and could help delay the onset of degenerative brain disorders, such as dementia.

Read more at: 

http://medicalxpress.com/news/2013-05-scientists-reveal-champagne-memory.html

Glenmark Generics receives final ANDA approvals for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg


May 15, 2013: Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approvals (ANDA’s) from the United States Food and Drug

Administration (US FDA) for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg. Glenmark will commence distribution of the product immediately. 

Zolmitriptan Tablets and Zolmitriptan ODT are Glenmark’s generic versions of Zomig® and Zomig ZMT® by AstraZeneca, indicated for the acute treatment of migraine headaches in adults.

According to IMS Health for the 12 month period ending December 2012, the products garnered annual sales of USD 176 million.

UK researchers have developed an injectable microgel that can completely restore the mechanical function of damaged spinal discs – at least in an animal model.


Back problems could be tackled with an injectable microgel

Back problems could be tackled with an injectable microgel

read all at

http://www.rsc.org/chemistryworld/2012/08/new-gel-repairs-damaged-discs

Sound approach to drug testing


pipette

read all at

 

http://www.rsc.org/chemistryworld/2013/05/sound-approach-drug-testing-acoustic-dispensing

Experimental Drug Seems to Aid Memory in Mice With Alzheimer’s


//

TUESDAY May 14, 2013 — An experimental drug improved the memory and brain function in older mice with advanced symptoms of Alzheimer’s disease, according to a new study.

read this at

http://www.drugs.com/news/experimental-seems-aid-memory-mice-alzheimer-s-44538.html

Quizartinib — a Phase 2B trial treatment for acute myeloid leukemia


 

quizartinib

Ambit Biosciences

 13 MAY 2013

Ambit Biosciences (NASDAQ:AMBI) is a biotech company that focuses on treatments that inhibit kinases, which are drivers for diseases such as cancer. Three drugs are in development, with the lead one being quizartinib — a Phase 2B trial treatment for acute myeloid leukemia.

However, AMBI’s collaboration agreement with Astellas Pharma (OTC:ALPMY) is set to expire in September, and if it is not replaced, it could mean a delay in Phase 3 trials for quizartinib. Keep in mind that AMBI generated $23.8 million in collaboration revenues last year.

 

Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor that is currently under development for the treatment of acute myeloid leukaemia. Its molecular target isFLT3, also known as CD135 which is a proto-oncogene.[1]

Flt3 mutations are among the most common mutations in acute myeloid leukaemia due tointernal tandem duplication of Flt3. The presence of this mutation is a marker of adverse outcome.

Specifically, Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs).Mutations cause constitutive action of Flt3 leading to resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis

It had good results in a phase II clinical trial for refractory AML – particularly in patients who went on to have a stem cell transplant.[2]

 

  1.  Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S. (2009). “Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor”. Journal of Medicinal Chemistry 52 (23): 7808–7816.
  2.  Drug Tames Refractory AML. ASH Dec 2012

 

Drug Delivery With A Bang, Nanoscience: Chain-shattering polymeric therapeutics could release medicines on demand


A schematic of a chain-shattering polymer releasing drugs on demand in response to eithera UV or peroxide trigger.

 
DRUG FIREWORKS
Chain-shattering polymer releases drug on demand in response to a UV or peroxide trigger.
Credit: Adapted from Angew. Chem. Int. Ed.
 
READ ALL AT

‘Breakthrough’ Drugs Rising, Pharmaceuticals: New FDA program could cut time for approvals in half, but details are vague


read all at

 

http://cen.acs.org/articles/91/i19/BreakthroughDrugs-Rising.html

Process for the preparation of oseltamivir and methyl 3-epi-shikimate,Council Of Scientific & Industrial Research, INDIA


File:Oseltamivir.svg

oseltamivir

Process for the preparation of oseltamivir and methyl 3-epi-shikimate, for Influenza virus infection

WO 2013061340

BY

Rawat, Varun; Dey, Soumen; Arumugam, Sudalai

The present invention discloses high yielding enantioselective process for synthesis of Oseltamivir from readily available starting material, cis-1,4-butene diol.The process features incorporation of chirality using sharpless asymmetric epoxidation(AE) and diastereoselective Barbier allylation and construction of cyclohexene carboxylic acid ester core through a ring closing metathesis (RCM) reaction. Further also disclosed herein is synthesis of (-)-methyl 3-epi-shikimate.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=

20130502&CC=WO&NR=2013061340A1&KC=A1